News Related to CXCR2

Related coverage linked through entity extraction aliases.

New Cancer Research Shows Promise in Blood Cancer, Prostate Cancer, and Ovarian Cancer Treatment

Mar 17, 2026

Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.

Three Clinical Trial Pipeline Reports Track Progress in Prostate Cancer, NK Cells, and Lung Diseases

Feb 15, 2026

DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.